Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016640 | 1.00 | XDH (0.50) | XDHSMN1; SMN2TMIGD3HTR2CHTR2B | |
| SCHEMBL6016639 | 0.81 | EGFR (0.42) | SMN1; SMN2LMNAEGFR | |
| SCHEMBL7148659 | 0.81 | EGFR (0.42) | SMN1; SMN2LMNAEGFR | |
| SCHEMBL17933836 | 0.81 | SMN1; SMN2 (0.66) | XDHSMN1; SMN2TMIGD3HTR2CHTR2B | |
| SCHEMBL6016697 | 0.81 | LMNA (0.66) | SMN1; SMN2PIK3CDLMNAHSD17B10EGFR | |
| SCHEMBL6016698 | 0.81 | LMNA (0.66) | SMN1; SMN2PIK3CDLMNAHSD17B10EGFR | |
| SCHEMBL3445625 | 0.81 | EGFR (0.39) | SMN1; SMN2LMNAEGFR | |
| SCHEMBL3445624 | 0.81 | EGFR (0.39) | SMN1; SMN2LMNAEGFR | |
| SCHEMBL7711077 | 0.78 | SMN1; SMN2 (0.53) | XDHSMN1; SMN2TMIGD3HTR2CHTR2B | |
| SCHEMBL14662045 | 0.74 | EGFR (0.46) | SMN1; SMN2LMNAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187261-A1 | Purine derivatives, process for their preparation and use thereof | USTAV EXPERIMANTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2003-10-02 | — | — | US | claimed |
| US-20030187261-A1 | Purine derivatives, process for their preparation and use thereof | USTAV EXPERIMANTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187261-A1 | Purine derivatives, process for their preparation and use thereof | DCK, DTYMK, CCNK | XDH 732/4885SMN1; SMN2 2887/4885TMIGD3 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.